129 related articles for article (PubMed ID: 22049994)
1. Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.
Yamamoto Y; Tsuzuki S; Akahori Y; Ukai Y; Sumitomo M; Murayama Y; Yamamoto K; Inaguma Y; Tokuda M; Abe A; Akatsuka Y; Emi N; Kurosawa Y
Cancer Sci; 2012 Feb; 103(2):350-9. PubMed ID: 22049994
[TBL] [Abstract][Full Text] [Related]
2. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
3. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
[TBL] [Abstract][Full Text] [Related]
5. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
6. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
Youssoufian H; Rowinsky EK; Tonra J; Li Y
Cancer; 2010 Feb; 116(4 Suppl):1013-7. PubMed ID: 20127944
[TBL] [Abstract][Full Text] [Related]
7. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
Kasper S; Breitenbuecher F; Hoehn Y; Heidel F; Lipka DB; Markova B; Huber C; Kindler T; Fischer T
Leuk Res; 2008 Nov; 32(11):1698-708. PubMed ID: 18556063
[TBL] [Abstract][Full Text] [Related]
8. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
9. Effects of Flt3 ligand and interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells.
Eder M; Hemmati P; Kalina U; Ottman OG; Hoelzer D; Lyman SD; Ganser A
Exp Hematol; 1996 Feb; 24(2):371-7. PubMed ID: 8641368
[TBL] [Abstract][Full Text] [Related]
10. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
Kiyoi H; Shiotsu Y; Ozeki K; Yamaji S; Kosugi H; Umehara H; Shimizu M; Arai H; Ishii K; Akinaga S; Naoe T
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4575-82. PubMed ID: 17671144
[TBL] [Abstract][Full Text] [Related]
11. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
12. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
13. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
14. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
Leuk Res; 2007 Jun; 31(6):791-7. PubMed ID: 17156841
[TBL] [Abstract][Full Text] [Related]
15. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells.
Dehmel U; Zaborski M; Meierhoff G; Rosnet O; Birnbaum D; Ludwig WD; Quentmeier H; Drexler HG
Leukemia; 1996 Feb; 10(2):261-70. PubMed ID: 8637235
[TBL] [Abstract][Full Text] [Related]
16. Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.
Williams B; Atkins A; Zhang H; Lu D; Jimenez X; Li H; Wang MN; Ludwig D; Balderes P; Witte L; Li Y; Zhu Z
Leukemia; 2005 Aug; 19(8):1432-8. PubMed ID: 15931264
[TBL] [Abstract][Full Text] [Related]
17. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
Masson K; Rönnstrand L
Cell Signal; 2009 Dec; 21(12):1717-26. PubMed ID: 19540337
[TBL] [Abstract][Full Text] [Related]
19. Discovery of quinolinone derivatives as potent FLT3 inhibitors.
Chung HJ; Kamli MR; Lee HJ; Ha JD; Cho SY; Lee J; Kong JY; Han SY
Biochem Biophys Res Commun; 2014 Mar; 445(3):561-5. PubMed ID: 24530392
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
